PMID- 38049207
OWN - NLM
STAT- MEDLINE
DCOM- 20240219
LR  - 20240219
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
VI  - 44
IP  - 2
DP  - 2024 Feb
TI  - Pain management considerations in patients living with both pain syndromes and 
      cardiovascular diseases and disorders.
PG  - 184-196
LID - 10.1002/phar.2897 [doi]
AB  - Concomitant pain syndromes and cardiovascular disease (CVD) and disorders are 
      associated with significant morbidity, impaired quality of life, and 
      neuropsychiatric disorders. There is an interplay between the mechanisms of 
      pathophysiology of both CVD and pain syndromes. Patients with CVD (and/or 
      disorders) as well as pain syndromes have an increased propensity for 
      drug-drug/disease interactions. Therefore, an understanding of how to use 
      pharmacotherapy to treat pain syndromes, in the context of patients who have 
      diagnoses of CVD and/or disorders, is paramount to patients' success in achieving 
      adequate pain control and appropriately managing CVD and/or disorders, all while 
      decreasing the risk of adverse events (AEs) both from pharmacotherapy to treat 
      pain and CVD (and/or disorders). Based on the appraisal of literature and 
      authors' clinical expertise, it was determined that gabapentinoids, opioids, 
      skeletal muscle relaxants, tricyclic antidepressants, clonidine, serotonin 
      norepinephrine-reuptake inhibitors, dronabinol, carbamazepine, second-generation 
      antipsychotics, non-steroidal anti-inflammatory drugs, aspirin, corticosteroids, 
      and topical anesthetics have the most evidence for use in patients with CVD 
      and/or disorders. However, the literature surrounding the use of pharmacotherapy 
      for pain management is limited to retrospective studies and there is a lack of 
      well-designed, prospective, randomized trials; this also includes head-to-head 
      comparator studies. Unlike many CVD-related pharmacotherapy studies, data 
      studying pain management in patients with CVD lacks standardized outcomes that 
      are consistent among the pool of data. Overall, the decision to prescribe 
      specific pain management therapies in patients with CVD and/or disorders should 
      include assessment of pain severity, type of pain, drug-drug/disease 
      interactions, adjuvant therapies required, and the risk or presence of AEs.
CI  - (c) 2024 Pharmacotherapy Publications, Inc.
FAU - Leppien, Emily E
AU  - Leppien EE
AD  - Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 
      Binghamton University, Johnson City, New York, USA.
FAU - Pauling, Erin E
AU  - Pauling EE
AUID- ORCID: 0000-0003-2740-8789
AD  - Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 
      Binghamton University, Johnson City, New York, USA.
FAU - Smith, Eric
AU  - Smith E
AD  - School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson 
      City, New York, USA.
FAU - Wisniewski, Brady
AU  - Wisniewski B
AD  - School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson 
      City, New York, USA.
FAU - Carpenter, Abigayle
AU  - Carpenter A
AD  - School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson 
      City, New York, USA.
FAU - Schwier, Nicholas C
AU  - Schwier NC
AUID- ORCID: 0000-0002-7295-0676
AD  - Office of Experiential Education & Department of Pharmacy Practice, School of 
      Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, New 
      York, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240125
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Selective Serotonin Reuptake Inhibitors)
SB  - IM
MH  - Humans
MH  - *Pain Management
MH  - *Cardiovascular Diseases/drug therapy
MH  - Retrospective Studies
MH  - Prospective Studies
MH  - Quality of Life
MH  - Selective Serotonin Reuptake Inhibitors
MH  - Pain/drug therapy
OTO - NOTNLM
OT  - cardiovascular diseases drug-related side effects and adverse reactions
OT  - drug therapy
OT  - pain
EDAT- 2023/12/05 00:42
MHDA- 2024/02/19 06:43
CRDT- 2023/12/04 20:53
PHST- 2023/09/25 00:00 [revised]
PHST- 2023/06/30 00:00 [received]
PHST- 2023/09/26 00:00 [accepted]
PHST- 2024/02/19 06:43 [medline]
PHST- 2023/12/05 00:42 [pubmed]
PHST- 2023/12/04 20:53 [entrez]
AID - 10.1002/phar.2897 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2024 Feb;44(2):184-196. doi: 10.1002/phar.2897. Epub 2024 Jan 
      25.